TrialCompass TCL
Back to results
Phase 3Enrolling by invitationPriority 1 · Highest priorityNCT07258680

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Doxorubicin (DRUG): doxorubicin 50 mg/m2, day 1 | Vincristine (DRUG): vincristine 1.4 mg/m2, (maximum dose 2 mg) day 1 | Etoposide (DRUG): Etoposide 100 mg/m2, 1-3 days | cyclophosphamide (DRUG): cyclophosphamide 750 mg/m2, day 1 | Prednisone (DRUG): prednisone 100 mg, 1-5 days | Brentuximab Vedotin (Bv) (DRUG): brentuximab vedotin 1.8 mg / kg, day 1

Drugs / treatments
Doxorubicin, Vincristine, Etoposide, cyclophosphamide, Prednisone, Brentuximab Vedotin (Bv)
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680

Phase: Phase 3 | Status: Enrolling by invitation | Priority: Highest

Plain-language summary

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Doxorubicin (DRUG): doxorubicin 50 mg/m2, day 1 | Vincristine (DRUG): vincristine 1.4 mg/m2, (maximum dose 2 mg) day 1 | Etoposide (DRUG): Etoposide 100 mg/m2, 1-3 days | cyclophosphamide (DRUG): cyclophosphamide 750 mg/m2, day 1 | Prednisone (DRUG): prednisone 100 mg, 1-5 days | Brentuximab Vedotin (Bv) (DRUG): brentuximab vedotin 1.8 mg / kg, day 1

Drugs / treatments: Doxorubicin, Vincristine, Etoposide, cyclophosphamide, Prednisone, Brentuximab Vedotin (Bv)

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 114 patients

Primary endpoint: complete response rate

Ages: 18 Years to 70 Years

Start date: 2013-10 | Est. completion: 2028-12

Locations

0 US sites · 0 total

Contact

—

Sponsor: N.N. Petrov National Medical Research Center of Oncology (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07258680

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.